润都股份：将持续关注新型烟草终端产品的发展趋势

Core Viewpoint - The company has submitted a registration application for its innovative drug, and its nicotine product has seen significant sales growth, although it has not yet impacted overall performance [1] Group 1: Drug Development - The company’s innovative drug, hydrochloride dextromethorphan injection, submitted a registration application to the National Medical Products Administration in March 2024, which has been accepted [1] - In December 2024, the company received a notice for supplementary pharmaceutical data, with supplementary research expected to be completed by April 2025 [1] - The relevant procedures have entered the subsequent review sequence, and the company will disclose any significant progress in accordance with information disclosure regulations [1] Group 2: Nicotine Product - The company’s wholly-owned subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., has received widespread recognition for its nicotine quality, which is used in the production of new tobacco products [1] - Sales of the nicotine product significantly increased in the first half of the year [1] - Currently, this business has not had a major impact on the company’s overall operating performance, but the company will continue to monitor trends in new tobacco terminal products and seek cooperation and development opportunities [1]